Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 12 August 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1676745

Correction: Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

This article is a correction to:

  1. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

    1. Read original article
Zhanzhan LiZhanzhan Li1Yanyan LiYanyan Li2Yifu TianYifu Tian3Na LiNa Li1Liangfang ShenLiangfang Shen1Yajie Zhao,*Yajie Zhao4,5*
  • 1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China
  • 2Department of Nursing, Xiangya Hospital, Central South University, Changsha, Hunan, China
  • 3Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China
  • 4Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China
  • 5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China

A Correction on
Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

By Li Z, Li Y, Tian Y, Li N, Shen L and Zhao Y (2023) Front. Immunol. 14:1170539. doi: 10.3389/fimmu.2023.1170539

In the published article, there were errors in the Funding statement. The Funding statement is incomplete. The correct Funding statement appears below.

“This study was supported by the National Natural Science Foundation of China (LZZ: No.82003239), Hunan Provincial Natural Science Foundation of China (LZZ: No.2023JJ30907), and National key clinical specialty (SLF: 2209090720).”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Keywords: TMSB10, pan-cancer, immunotherapy, prognosis, immune infiltration

Citation: Li Z, Li Y, Tian Y, Li N, Shen L and Zhao Y (2025) Correction: Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response. Front. Immunol. 16:1676745. doi: 10.3389/fimmu.2025.1676745

Received: 31 July 2025; Accepted: 01 August 2025;
Published: 12 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Li, Li, Tian, Li, Shen and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yajie Zhao, enlqaWU1OTc3QGNzdS5lZHUuY24=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.